Everything tagged "medical devices" across the TickerSpark archives.
22 articles
Insulet is delivering strong Omnipod-driven growth, with Q1 revenue up 33.9% and guidance raised for 2026. The stock looks attractive for growth investors, but its premium valuation and execution risk keep the case from being low-risk.
Medline is growing quickly, but heavy debt and margin pressure keep the stock in disciplined Buy territory. The report sees solid medium-term upside, with fair value above the recent trading price.
Fresenius Medical Care is a Hold as improving margins and cost savings offset sluggish revenue growth and looming reimbursement pressure. The dialysis leader’s 5008X rollout and clinic rationalization support earnings, but the stock already sits near fair value.
Stryker’s Q2 execution, Mako robotics momentum, and raised full-year outlook support a Buy, though valuation leaves limited room for error. Cybersecurity, supply disruption, and tariff pressure keep the risk profile disciplined.
Three medical-device stocks are ranked by investment quality, with women’s health, orthopedics, robotics, and diversified MedTech driving the countdown.
GE HealthCare offers a credible Buy case built on recurring service revenue, diagnostics, and a broad global installed base. Upside is supported by cash generation and innovation, but earnings volatility and leverage keep the story from being low risk.
Align Technology combines a strong balance sheet, improving margins, and a leading Invisalign franchise, but 2026 growth guidance remains modest. The stock looks attractive for moderate-risk investors if margin recovery and international demand continue to build.
Alcon is pairing strong Unity equipment momentum with faster dry-eye growth, while cash flow and buybacks support the bull case. Valuation is not cheap, but guidance and mix shift keep the stock constructive.
Intuitive Surgical just got hit like the growth story broke, yet the quarter said the opposite. Revenue rose 19%, procedures stayed double-digit, and da Vinci 5 placements kept climbing, which makes this look more like an expectations reset than a business problem.
Abbott is evolving from a defensive healthcare name into a stronger medtech-led compounder, helped by Medical Devices growth and the Exact Sciences deal. Nutrition remains a drag, but the stock looks attractive on weakness rather than at any price.
Intuitive Surgical continues to compound through rising procedures, a larger installed base, and an increasingly recurring revenue mix. The main debate is whether that quality justifies the stock’s premium valuation.
Intuitive Surgical trades at a premium because it is still delivering premium operating results. With procedure growth running around 17%, revenue up 20.5%, and the da Vinci installed base still expanding double digits, the usual "too expensive" knock misses what the business is actually doing.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime